Leonard Sadoff, M.D.
This content is PDF only. Please click on the PDF icon to access.
Although the important role of progestational agents in the palliation of advanced endometrial cancer is well established, the beneficial effect of progestins in other malignancies is not generally appreciated. British investigators, in particular, have reported objective remissions with the use of progestins in cancer of the kidney, breast, ovary, and prostate. During the past 2 years we have treated more than 30 patients with medroxyprogesterone acetate, a potent synthetic progestational steroid, at doses ranging from 300 mg daily to 600 mg weekly, intramuscularly. Objective antitumor responses were seen in 4 of 20 patients with female breast carcinoma; 2 of 2,
Leonard Sadoff. The Usefulness of Medroxyprogesterone Acetate in the Treatment of Advanced Cancer.. Ann Intern Med. 1973;78:830–831. doi: 10.7326/0003-4819-78-5-830_5
Download citation file:
Published: Ann Intern Med. 1973;78(5):830-831.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use